Patients were randomly assigned to receive the NS@A inhibitor ledipasvir and the nucleotide polymerase inhibitor sofosbuvir in a once-daily , fixed-dose combination tablet for @ weeks , ledipasvir-sofosbuvir plus ribavirin for @ weeks , ledipasvir-sofosbuvir for @ weeks , or ledipasvir-sofosbuvir plus ribavirin for @ weeks .